Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › secukinumab

secukinumab

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of secukinumab

48 trials tracked of secukinumab: 40 in phase 3 or 4 and 23 with published results. The most-cited published study has 372 citations.

48Trials tracked
40Phase 3 & 4
0Recruiting
23With published results
Phase distribution
Phase 4 6 Phase 3 34 Phase 2 8
  1. Phase 3 A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis Completed · 372 cited
  2. Phase 3 Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis Completed · 299 cited
  3. Phase 3 Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) Completed · 298 cited
  4. Phase 3 This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). Completed · 296 cited
  5. Phase 3 Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis Completed · 282 cited
  6. Phase 3 Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement Completed · 188 cited
Show 42 more trials
  1. Phase 3 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis Completed · 167 cited
  2. Phase 3 Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis Completed · 159 cited
  3. Phase 3 Extension in AS: Sustainability of Benefits, Safety and Tolerability Completed · 142 cited
  4. Phase 3 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis Completed · 84 cited
  5. Phase 3 Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis Completed · 75 cited
  6. Phase 3 Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) Completed · 75 cited
  7. Phase 4 A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. Completed · 70 cited
  8. Phase 3 Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis Completed · 70 cited
  9. Phase 3 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis Completed · 70 cited
  10. Phase 3 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients Completed · 70 cited
  11. Phase 3 Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Completed · 70 cited
  12. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 39 cited
  13. Phase 3 A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Completed · 28 cited
  14. Phase 3 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis Completed · 25 cited
  15. Phase 3 Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site Completed · 18 cited
  16. Phase 4 Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients Completed
  17. Phase 4 Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis Completed
  18. Phase 4 Immunologic Response to Secukinumab in Plaque Psoriasis Completed
  19. Phase 4 Brain Changes in Psoriasis After Secukinumab Treatment Completed
  20. Phase 4 Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome Completed
  21. Phase 3 Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab Completed
  22. Phase 3 Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. Completed
  23. Phase 3 Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis Completed
  24. Phase 3 Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers Completed
  25. Phase 3 Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) Completed
  26. Phase 3 Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis Completed
  27. Phase 3 A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) Completed
  28. Phase 3 Plaque Psoriasis Efficacy and Safety With Secukinumab Completed
  29. Phase 3 Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis Completed
  30. Phase 3 Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA Completed
  31. Phase 3 An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) Completed
  32. Phase 3 Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment Completed
  33. Phase 3 Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy Completed
  34. Phase 3 Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis Completed
  35. Phase 2 The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Completed
  36. Phase 2 Secukinumab for Treatment of Atopic Dermatitis Completed
  37. Phase 2 A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis Completed
  38. Phase 2 Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy Completed
  39. Phase 2 Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients Completed
  40. Phase 2 A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients Completed
  41. Phase 2 Safety and Efficacy of Secukinumab in Mild Psoriasis Completed
  42. Phase 2 Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea Completed

Showing the 48 most-cited and recently-updated of 48 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Secukinumab improves skin response in Chinese patients with psoriatic arthritis
Rheumatology Cohort
Secukinumab improves skin response in Chinese patients with psoriatic arthritis Secukinumab linked to skin improvement in Chinese psoriatic arthritis patients
This observational cohort study of 446 Chinese patients with psoriatic arthritis found that treatment with secukinumab for over 12 weeks was…
In Chinese psoriatic arthritis patients, secukinumab treatment was associated with significant skin improvement and better quality of life o…
Frontiers Apr 23, 2026
Secukinumab 300 mg subcutaneously failed to demonstrate overall response in adults with active Graves orbitopathy versus placebo
Diabetes & Endocrinology RCT
Secukinumab 300 mg subcutaneously failed to demonstrate overall response in adults with active Graves orbitopathy versus placebo Secukinumab showed no benefit for active Graves orbitopathy patients
This randomized, double-blind, placebo-controlled trial evaluated secukinumab versus placebo in 28 adults with active, moderate-to-severe…
Secukinumab treatment for Graves orbitopathy showed no improvement in symptoms or eye measurements compared to placebo treatment.
Apr 22, 2026
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
Dermatology FDA Approval
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older The FDA has approved a new drug called Cosentyx for treating a serious skin condition
The FDA approved Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are c…
The FDA approved Cosentyx for moderate to severe plaque psoriasis in adults and children 6 and older.
FDA Apr 22, 2026
FDA Approves Cosentyx (secukinumab) for Moderate to Severe Hidradenitis Suppurativa in Adults and Pediatric Patients
Dermatology FDA Approval
FDA Approves Cosentyx (secukinumab) for Moderate to Severe Hidradenitis Suppurativa in Adults and Pediatric Patients The FDA approved a new use for the drug Cosentyx to treat a painful skin condition
The FDA has approved Cosentyx for moderate to severe hidradenitis suppurativa in adults and pediatric patients 12 years and older.
The FDA has approved Cosentyx for treating moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps.
FDA Apr 22, 2026
Case report describes secukinumab use in a woman with erythrodermic psoriasis and systemic capillary leak syndrome
Diabetes & Endocrinology Sys. Review
Case report describes secukinumab use in a woman with erythrodermic psoriasis and systemic capillary leak syndrome One case report links secukinumab to severe capillary leak syndrome in a woman with psoriasis
This case report details the clinical course of a 66-year-old woman with new-onset erythrodermic psoriasis who developed systemic capillary …
A woman with psoriasis developed life-threatening capillary leak syndrome after starting secukinumab, with symptoms improving only after sto…
Frontiers Apr 21, 2026
Secukinumab improves cutaneous adipose tissue inflammatory signatures in psoriasis patients
Diabetes & Endocrinology RCT
Secukinumab improves cutaneous adipose tissue inflammatory signatures in psoriasis patients Fat Under Your Skin Fuels Psoriasis Inflammation
This randomized placebo-controlled trial evaluated secukinumab in 82 patients with psoriasis.
Your body fat is not just storing energy; it is actively making your psoriasis worse, and new treatments are finally targeting this hidden f…
Apr 10, 2026